Last reviewed · How we verify
GFH009
At a glance
| Generic name | GFH009 |
|---|---|
| Sponsor | Genfleet Therapeutics (Shanghai) Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML (PHASE1, PHASE2)
- A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL (PHASE1, PHASE2)
- A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GFH009 CI brief — competitive landscape report
- GFH009 updates RSS · CI watch RSS
- Genfleet Therapeutics (Shanghai) Inc. portfolio CI